Nearly 15% of King County children received MMRV as their first measles- or varicella-containing vaccine between 2015 and 2025, a share that did not change despite ACIP's longstanding preference for ...
THRIVE is the first phase 2 study to evaluate the VIASKIN Peanut Patch in infants aged 6 to 12 months with peanut allergy. Investigators will assess whether early epicutaneous immunotherapy can enable ...
THRIVE is the first study to evaluate the VIASKIN Peanut Patch in infants aged 6 to 12 months with confirmed peanut allergy. Investigators hope intervention during infancy may alter the long-term ...
A look back at the latest clinical trial updates for the pediatric population during June 2026. June brought a more concentrated set of clinical trial developments than earlier in the quarter, with ...
The July 1, 2026 decision makes exagamglogene autotemcel the first gene therapy approved for SCD in children younger than 12 years. The FDA has issued a supplemental approval for Casgevy ...
Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, and Attending Physician, Pediatric Emergency Medicine, Nemours/Alfred I duPont ...
A look back at the FDA approvals, label expansions, and regulatory decisions in the pediatric health care space from April through June 2026. Spring gave way to summer, and along the way the FDA kept ...
Any infant who consumed Nara Organics Whole Milk Organic Powdered Infant Formula and presents with constipation, poor feeding, hypotonia, loss of head control, or facial weakness should be evaluated ...
The FDA's Warning Letter identifies the SNOO X-Small and X-Large sleep sacks as unauthorized modifications to an FDA-cleared device; clinicians should caution families to discontinue use of these ...
Gadoquatrane (Ambelvist) is now the lowest-dose macrocyclic GBCA approved in the United States, delivering 0.04 mmol Gd/kg body weight — 60% less gadolinium than standard mGBCAs dosed at 0.1 mmol ...
The FDA has granted Orphan Drug Designation to para-chloro-phenylalanine (pCPA) for monoamine oxidase deficiency (MAOD), a rare X-linked neurodevelopmental disorder associated with impaired monoamine ...
In a parallel regulatory action, the European Medicines Agency has also validated a marketing application for Tivicay covering the neonatal indication. The FDA has accepted a supplemental new drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results